Successful desensitization of a patient with cetuximab hypersensitivity: A case report

Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
Mohammad SolduzianZahra Jahangard-Rafsanjani

Abstract

Severe hypersensitivity reaction is a dangerous adverse drug reaction in patients receiving cetuximab. It requires drug discontinuation and medical management. A 48-year-old man, previously diagnosed with metastatic colorectal cancer, was admitted for therapy continuation. During the first infusion of cetuximab, the patient experienced acute signs of hypersensitivity reactions. The treatment team decided to administer cetuximab employing the desensitization protocol. This study reports a severe hypersensitivity reaction to cetuximab in an adult patient with colorectal cancer. This patient was successfully managed with a new safe and rapid desensitization protocol.

References

Dec 6, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christophe TournigandAimery de Gramont
Oct 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Heinz-Josef LenzEric K Rowinsky
Aug 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bert H O'NeilRichard M Goldberg
Nov 16, 2007·The New England Journal of Medicine·Derek J JonkerMalcolm J Moore
Mar 14, 2008·The New England Journal of Medicine·Christine H ChungThomas A E Platts-Mills
Jul 22, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard S HochsterEric Hedrick
Nov 22, 2008·The Journal of Allergy and Clinical Immunology·Maya R JerathTeresa K Tarrant
Apr 3, 2009·The New England Journal of Medicine·Eric Van CutsemPhilippe Rougier
Feb 12, 2010·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Nicole L HansenRichard A Hansen
Aug 19, 2010·Allergy·J R CernadasUNKNOWN European Network of Drug Allergy and the EAACI interest group on drug hypersensitivity
Dec 14, 2011·Expert Review of Clinical Immunology·David I HongMariana C Castells
May 11, 2016·Journal of Investigational Allergology & Clinical Immunology·J M García-MenayaP Bobadilla-González
Jul 7, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Van CutsemD Arnold

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.